Answers are grounded in this paper and cite their sources.
Psoriasis is a chronic inflammatory skin disease characterized by dysregulated innate and adaptive immune responses. The antimicrobial peptide LL-37 is increased in psoriatic skin and can promote inflammation through effects on cellular damage, leukocyte recruitment, cytokine production, and the formation of immunostimulatory complexes with self-derived nucleic acids. Here, we investigated whether the human plasma protein apolipoprotein A-I (ApoA-I) can regulate LL-37 activity and thereby attenuate psoriasis-associated inflammation. We show that ApoA-I acts as a scavenger of LL-37 and that its administration confers therapeutic benefits in psoriatic skin, as demonstrated in an experimental animal model and human ex vivo models. Mechanistically, ApoA-I limited nucleic acid uptake and TLR-dependent type I interferon responses in plasmacytoid dendritic cells and keratinocytes. In an experimental mouse model, ApoA-I attenuated imiquimod-induced psoriasiform inflammation, reducing clinical, histological, and molecular disease features, while also suppressing inflammatory mediators and psoriasis-associated biomarkers in a human 3D psoriatic skin model. Together, these findings identify ApoA-I as a previously unrecognized regulator of LL-37-driven skin inflammation and suggest that therapeutic strategies aimed at restoring or mimicking ApoA1´s LL-37-scavenging mechanisms may have potential for treatment of psoriasis and related inflammatory skin diseases.
No takes yet. Share an insight, caveat, or question.
Kozieł et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: